GlassScriptPhysician profile
Mark Alexander Johnson
NPI 1376707034
$9,577.71
in general payments reported to CMS, 2019-2025
56 companies · $1,511 in 2025
The $1,511 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,525 · 2020: $368 · 2021: $179 · 2022: $2,189 · 2023: $1,726 · 2024: $2,080 · 2025: $1,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,316.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,928.57 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $989.34 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $896.51 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $604.73 | 2019-2024 | Emgality, Mounjaro, Reyvow |
| Abbvie INC. | $590.09 | 2021-2025 | |
| Novo Nordisk INC | $516.52 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $374.26 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Teva Pharmaceuticals USA, INC. | $249.95 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $232.95 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $226.35 | 2019-2025 | |
| Antares Pharma, INC. | $205.47 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Sanofi-Aventis U.S. LLC | $193.24 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.28 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $172.67 | 2019-2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $144.73 | 2024-2025 | Voquezna |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $144.44 | 2019-2024 | Spravato |
| Merck Sharp & Dohme LLC | $138.08 | 2019-2025 | Capvaxive, Rotateq, M-M-R II |
| Shield Therapeutics INC | $135.76 | 2024 | |
| Exact Sciences Corporation | $125.24 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $124.65 | 2020-2025 | Freestyle Libre 3, Proclaim |
| Allergan, INC. | $122.46 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.39 | 2019-2024 | Xifaxan, Trulance |
| Corcept Therapeutics | $107.53 | 2022-2025 | Korlym |
| Dexcom, INC. | $99.47 | 2023-2025 | Dexcom G6 Transmitter |
| Corium, LLC | $85.41 | 2022-2024 | Azstarys |
| Axsome Therapeutics, INC. | $73.40 | 2023-2025 | Auvelity, Symbravo |
| Astellas Pharma US INC | $72.68 | 2019-2023 | Veozah |
| Ironshore Pharmaceuticals INC. | $64.04 | 2019-2023 | Jornay Pm |
| Halozyme INC | $63.75 | 2023 | |
| Edwards Lifesciences Corporation | $56.55 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Xeris Pharmaceuticals, INC. | $47.09 | 2025 | Recorlev |
| Exeltis, USA INC. | $41.59 | 2022 | |
| Genentech USA, INC. | $31.85 | 2020 | |
| Lucid Diagnostics INC. | $29.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.83 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.30 | 2022 | |
| Medtronic, INC. | $25.80 | 2025 | Inceptiv |
| Eisai INC. | $23.10 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $22.75 | 2024 | |
| Kyowa Kirin, INC. | $20.42 | 2024 | Crysvita |
| Mylan Specialty L.P. | $20.01 | 2022 | |
| Collegium Pharmaceutical, INC. | $18.80 | 2025 | Jornay Pm |
| Lundbeck LLC | $18.74 | 2022 | |
| Alnylam Pharmaceuticals INC. | $18.48 | 2021 | |
| Mayne Pharma Commercial LLC | $17.76 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.52 | 2025 | Caplyta |
| Medtronic USA, INC. | $15.50 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.05 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $15.02 | 2025 | Zoryve |
| Therapeuticsmd, INC. | $14.21 | 2019 | |
| Organon LLC | $13.77 | 2022 | |
| Supernus Pharmaceuticals, INC. | $13.68 | 2022 | Xyosted |
| Ucb, INC. | $13.64 | 2020 | |
| Idorsia Pharmaceuticals US INC | $12.98 | 2023 | Quviviq |
| Amneal Pharmaceuticals LLC | $12.08 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.23 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.